Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer | MRK Stock News

Friday, 22 September 2023, 13:00:00
Merck, known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3
— Stock Titan

Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

Friday, 22 September 2023, 12:59:35
Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. (SGEN) and Astellas Pharma Inc. (ALPMY.PK, ALPMY).
— RTT News

Merck succeeds in Phase 3 trial for bladder cancer therapy

Friday, 22 September 2023, 12:49:12
Merck”s Keytruda and Seagen”s Padcev met primary endpoints in a Phase 3 trial for bladder cancer, showing significant improvements over chemotherapy. Read more here.
— Seeking Alpha

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Friday, 22 September 2023, 12:45:00
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic non-small cell lung cancer. This press release features
— Wallstreet:Online

Merck: Still Fundamentally Undervalued Considering Keytruda”s Prospects

Thursday, 21 September 2023, 16:00:00
Keytruda is proving effective in treating more and more types of cancer. Read here to know how this impacts MRK stock”s revenue and profitability going forward.
— Seeking Alpha